Evidence of Barrier Deficiency in Rosacea and the Importance of Integrating OTC Skincare Products into Treatment Regimens
Hilary Baldwin MD, Andrew F. Alexis MD MPH, Anneke Andriessen PhD, Diane S. Berson MD FAAD, Patricia Farris MD FAAD, Julie Harper MD, Edward Lain MD FAAD, Shari Marchbein MD, Linda Stein Gold MD, Jerry Tan FRCPC
Rosacea, an inflammatory skin disease that leads to an impaired skin barrier function commonly involves the face. Symptoms of rosacea can be bothersome and include pain, stinging, burning, itching, and facial flushing. This review explored skin barrier impairment in rosacea and reduced symptomatology when using over the counter (OTC) skincare products.
Nine dermatologists (the panel) completed a survey on OTC products they recommend for rosacea. The survey results were summarized, presented, and discussed during the online meeting, together with the results of a literature review. The outcome of these discussions, coupled with the panel’s expert opinion and experience, is shown in the current review. J Drugs Dermatol. 2020(4):384-392. doi:10.36849/JDD.5861
Oral Sarecycline for Treatment of Papulopustular Rosacea: Results of a Pilot Study of Effectiveness and Safety
James Q. Rosso DO, Zoe Diana Draelos MD, Cheryl Effron MD, Leon H. Kircik MD
Cutaneous rosacea is a common inflammatory skin disorder that often presents with facial papulopustular lesions that are frequently bothersome to patients. Studies have shown oral sarecycline to be effective and safe for acne, with a low risk of side effects that are historically associated with other tetracycline-class drugs such as doxycycline and minocycline, in addition to offering a reduced risk of emergence of resistant bacteria due to its narrow-spectrum of antibiotic activity.
Linda Stein Gold MD, Hilary Baldwin MD, Julie C. Harper MD
Rosacea is a chronic, multifactorial condition associated with various phenotypes affecting the centrofacial skin.1 The primary diagnostic phenotypes for rosacea, as defined by the National Rosacea Society, include fixed centrofacial erythema with periodic intensification, and phymatous changes.2 Major phenotypes, which may occur concomitantly or independently with the diagnostic features, are papules and pustules, flushing, telangiectasia, and ocular manifestations. Secondary signs and symptoms also may occur with the diagnostic or major phenotypes; these may include burning or stinging sensations, facial edema, and a dry appearance of central facial skin. J Drugs Dermatol. 2020;19(10): 929-934. doi:10.36849/JDD.2020.5367
Rosacea is a disease resulting from dysregulation of innate, adaptive, and neurovascular immune systems. Inflammatory pathways activated in rosacea can explain many of its signs and symptoms. Current treatments address some of these inflammatory processes, alleviating erythema and decreasing papules and pustules. However, for the majority of patients, complete clearance of these features is not currently achievable even with combination therapy. There is a need to address the spectrum of inflammatory processes involved in rosacea and for more efficacious agents with the goal of providing complete clearance for patients. J Drugs Dermatol. 2020;19(6): doi:10.36849/JDD.2020.5187
Sandra Marchese Johnson MD FAAD, Andrew Berg PA, Chelsea Barr MPAS PA-C
The goal of this article is to provide clinicians with the tools and understanding needed to correctly identify rosacea and differentiate it from other conditions that have overlapping signs and symptoms. Rosacea is a chronic inflammatory skin disease with a complex, multifactorial pathophysiology that remains to be fully understood. An enhanced immune response and neuroimmune/neurovascular alterations are thought to have a central role. J Drugs Dermatol. 2019;18(9):888-894.